Acer Therapeutics Inc. ACER Cash Flow

Acer therapeutics inc. (ACER)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Cash flows from operating activities:
Net loss
-26,397	-29,417	-32,757	-31,472	-25,265	-21,280	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-7,918	-6,699	-6,941	-9,436	-10,828	-12,019	-12,997	-14,081	-14,747	-15,052	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense
-	-	-	-	-	-	-	-	-	242	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
2,608	2,612	2,337	2,126	1,737	1,318	1,212	966	654	418	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	0	0	0	-	-	-	-
Restricted stock expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Depreciation
66	58	51	43	31	27	17	13	9	3	3	-132	-68	3	74	298	327	351	376	384	389	387	0	0	0
Write-off of deferred financing costs
-	-	-	-	-	-	-	-	-	1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Option expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-965	-948	-835	0	0	0	-	0	0	0
Changes in operating assets and liabilities
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-154	-267	-172	221	-47	193	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
283	-472	-565	677	-264	937	55	-164	-521	-287	356	944	790	140	-339	-570	-87	37	646	319	-42	6	0	0	0
Accrued expenses
-1,587	-2,602	595	1,301	606	2,609	-151	-897	-200	68	-237	348	177	-102	92	704	87	-41	-962	-876	-105	-183	0	0	0
Other non-current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	693	524	547	-548	-1,177	-1,014	-513	0	0	0
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,905	-2,905	443	2,272	2,691	3,110	138	0	0	0
Other noncurrent assets
-	-	-	-	-	6	0	0	0	-	-	-	-	-	-	-	-	-535	0	0	0	-	-	-	-
Net cash used in operating activities
-24,826	-29,506	-30,106	-27,481	-23,111	-16,587	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities:
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-6,485	-6,957	-8,054	-11,189	-12,648	-10,325	-10,535	-10,602	-10,508	-14,195	0	0	0
Purchase of property and equipment
-	178	136	215	174	95	0	0	0	-	-	-	-	-	-	-	86	92	111	75	121	190	0	0	0
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-1	-23	-81	-86	-92	-111	-75	-121	-190	0	0	0
Net cash used in investing activities
-	-178	-136	-215	-174	-95	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Common stock sold for cash net of offering cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Payment of deferred offering cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Note payable - insurance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	296	241	186	0	0	0	-	-	-	-
Costs associated with the issuance of common stock
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	50	-77	0	0	0	0	-	-	-	-
Deferred financing costs
-	-	-	-	-	-	-	-	-	68	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from convertible notes payable
-	-	-	-	-	-	-	-	-	5,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	11,139	7,994	8,488	835	13,117	13,095	12,601	12,747	543	648	0	0	0
Net cash provided by financing activities
-	-	-	-	-	42,710	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	5,835	9,545	13,810	4,186	6,446	4,652	1,035	410	-10,436	382	2,677	1,955	2,068	-10,086	-13,738	0	0	0
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	0	0	0	0
Cash paid during the year for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	2	2	1	3	2	1	0	0	0
Accretion of issuance costs on Series A Convertible Redeemable Preferred stock
-	-	-	-	-	-	-	-	-	51	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of issuance costs on Series B Convertible Redeemable Preferred stock
-	-	-	-	-	-	-	-	-	127	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid additions to property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Unpaid deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0